{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:44:16Z","timestamp":1792601056436,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s13555-025-01640-7","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:43:37Z","timestamp":1768416217000},"page":"1419-1425","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Improvement of Chronic Spontaneous Urticaria After Glucagon-Like Peptide\u00a01 Receptor Agonist Therapy: Report of Two Cases"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0090-8444","authenticated-orcid":false,"given":"Bart\u0142omiej","family":"Kwiek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Sieczych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"\u0141ukowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Ambroziak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"issue":"10","key":"1640_CR1","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa1215372","volume":"368","author":"M Maurer","year":"2013","unstructured":"Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924\u201335.","journal-title":"N Engl J Med"},{"issue":"10","key":"1640_CR2","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type\u00a02 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653\u201362.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"1640_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.40890","volume":"8","author":"P Li","year":"2025","unstructured":"Li P, Varghese JS, Shah MK, et al. Prescribing trends of glucagon-like peptide 1 receptor agonists for type\u00a02 diabetes or obesity. JAMA Netw Open. 2025;8(10):e2540890.","journal-title":"JAMA Netw Open"},{"key":"1640_CR4","doi-asserted-by":"publisher","first-page":"1148209","DOI":"10.3389\/fimmu.2023.1148209","volume":"14","author":"SF Mehdi","year":"2023","unstructured":"Mehdi SF, Pusapati S, Anwar MS, et al. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front Immunol. 2023;14:1148209.","journal-title":"Front Immunol"},{"key":"1640_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/diseases13050127","author":"C Persson","year":"2025","unstructured":"Persson C, Eaton A, Mayrovitz HN. A closer look at the dermatological profile of GLP-1 agonists. Dis. 2025. https:\/\/doi.org\/10.3390\/diseases13050127.","journal-title":"Dis"},{"issue":"9","key":"1640_CR6","volume":"17","author":"B Tassavor","year":"2025","unstructured":"Tassavor B, Al Salem S. Use of glucagon-like peptide-1 (GLP-1) agonists in modulating preexisting dermatologic disease: a systematic review. Cureus. 2025;17(9):e93282.","journal-title":"Cureus"},{"issue":"5","key":"1640_CR7","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.jaci.2017.11.043","volume":"142","author":"S Toki","year":"2018","unstructured":"Toki S, Goleniewska K, Reiss S, et al. Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group\u00a02 innate lymphoid cell cytokine production in vivo. J Allergy Clin Immunol. 2018;142(5):1515-28.e8.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1640_CR8","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jaad.2021.11.014","volume":"86","author":"YS Roh","year":"2022","unstructured":"Roh YS, Huang AH, Sutaria N, et al. Real-world comorbidities of atopic dermatitis in the US adult ambulatory population. J Am Acad Dermatol. 2022;86(4):835\u201345.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1640_CR9","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1007\/s00403-023-02636-z","volume":"315","author":"P Gupta","year":"2023","unstructured":"Gupta P, Bishnoi A, Bakshi S, Parsad D, Kumaran MS. Chronic spontaneous urticaria and metabolic syndrome: a relationship conundrum. Arch Dermatol Res. 2023;315(8):2445\u20138.","journal-title":"Arch Dermatol Res"},{"key":"1640_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70027","author":"E Kocaturk","year":"2025","unstructured":"Kocaturk E, Salameh P, Asero R, et al. Sex matters in CSU: women face greater burden and poorer urticaria control, especially in midlife-CURE insights. J Eur Acad Dermatol Venereol. 2025. https:\/\/doi.org\/10.1111\/jdv.70027.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10450","key":"1640_CR11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0140-6736(24)00852-3","volume":"404","author":"T Zuberbier","year":"2024","unstructured":"Zuberbier T, Ensina LF, Gimenez-Arnau A, et al. Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment. Lancet. 2024;404(10450):393\u2013404.","journal-title":"Lancet"},{"issue":"5","key":"1640_CR12","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1097\/ACI.0000000000001095","volume":"25","author":"B Wedi","year":"2025","unstructured":"Wedi B. Biologic and small molecule therapies in chronic spontaneous urticaria: an update. Curr Opin Allergy Clin Immunol. 2025;25(5):418\u201325.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"2","key":"1640_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.7326\/ANNALS-24-01590","volume":"178","author":"A Moiz","year":"2025","unstructured":"Moiz A, Filion KB, Toutounchi H, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes: a systematic review of randomized controlled trials. Ann Intern Med. 2025;178(2):199\u2013217.","journal-title":"Ann Intern Med"},{"issue":"3","key":"1640_CR14","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/all.15090","volume":"77","author":"T Zuberbier","year":"2022","unstructured":"Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI\/GA(2)LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734\u201366.","journal-title":"Allergy"},{"issue":"3","key":"1640_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nm.3804","volume":"21","author":"YH Youm","year":"2015","unstructured":"Youm YH, Nguyen KY, Grant RW, et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015;21(3):263\u20139.","journal-title":"Nat Med"},{"key":"1640_CR16","doi-asserted-by":"publisher","first-page":"1675552","DOI":"10.3389\/fphar.2025.1675552","volume":"16","author":"B Gong","year":"2025","unstructured":"Gong B, Li C, Shi Z, et al. GLP-1 receptor agonists: exploration of transformation from metabolic regulation to multi-organ therapy. Front Pharmacol. 2025;16:1675552.","journal-title":"Front Pharmacol"},{"issue":"7","key":"1640_CR17","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1111\/dom.16366","volume":"27","author":"Y Ren","year":"2025","unstructured":"Ren Y, Chen Y, Zheng W, et al. The effect of GLP-1 receptor agonists on circulating inflammatory markers in type\u00a02 diabetes patients: a systematic review and meta-analysis. Diabetes Obes Metab. 2025;27(7):3607\u201326.","journal-title":"Diabetes Obes Metab"},{"key":"1640_CR18","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-21-0007","author":"G Costanzo","year":"2021","unstructured":"Costanzo G, Curatolo S, Busa B, Belfiore A, Gullo D. Two birds one stone: semaglutide is highly effective against severe psoriasis in a type\u00a02 diabetic patient. Endocrinol Diabetes Metab Case Rep. 2021. https:\/\/doi.org\/10.1530\/EDM-21-0007.","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"10","key":"1640_CR19","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/jamadermatol.2025.2723","volume":"161","author":"L Gouvrion","year":"2025","unstructured":"Gouvrion L, Delage M, Villani AP, et al. Glucagon-like peptide-1 receptor agonists in hidradenitis suppurativa. JAMA Dermatol. 2025;161(10):1084\u20136.","journal-title":"JAMA Dermatol"},{"key":"1640_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.09.080","author":"SM Burke","year":"2025","unstructured":"Burke SM, Beveridge M, Hatipoglu B, Murphy J, Carroll BT. Association of GLP-1 agonist use with atopic dermatitis in obese patients: a retrospective cohort study. J Am Acad Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jaad.2025.09.080.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1640_CR21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.amjms.2025.07.006","volume":"370","author":"LB Afrin","year":"2025","unstructured":"Afrin LB, Weinstock LB, Dempsey TT, Aschenbrenner K, Blitshteyn S, Schofield JR. Utility of glucagon-like-peptide-1-receptor agonists in mast cell activation syndrome. Am J Med Sci. 2025;370(4):377\u201382.","journal-title":"Am J Med Sci"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01640-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01640-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01640-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T06:41:07Z","timestamp":1772001667000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01640-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1640"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01640-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Bartlomiej Kwiek reported serving as a clinical study investigator for AbbVie, Amgen inc, Arcutis Biotherapeuthics, Almirall, Aslan, Bristol-Myers Squibb, Celdex Therapeutics, Celltrion, Dermira, Galderma, Glenmark, Incyte, Janssen Pharmaceuticals, LEO Pharma, Novartis, Pfizer, Regeneron, Samsung. Julia Sieczych, Katarzyna \u0141ukowska, and Marcin Ambroziak declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is retrospective analysis of two cases. The review of the literature provided in the discussion part is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}